Zydus生命科学组织获得林业发展局对治疗5岁及以上病人的杜尚尼亚肌肉萎缩的通用Deflazacolt的核准。 Zydus Lifesciences gets FDA approval for generic Deflazacort to treat Duchenne muscular dystrophy in patients ages 5 and up.

Zydus生命科学组织已经获得美国林业发展局最终批准其通用Deflazacort口服悬浮(22.75毫克/毫升),以便在5岁及5岁以上的病人中治疗Duchenne肌肉萎缩症。 Zydus Lifesciences has received final U.S. FDA approval for its generic Deflazacort oral suspension, 22.75 mg/mL, to treat Duchenne Muscular Dystrophy in patients aged five and older. 类固醇药物可减少炎症,并调节免疫系统。 The steroid medication reduces inflammation and modulates the immune system. 批准标志着Zydus自2003-04年以来的第424届FDA批准, Manufactured in Doppel, Italy, the approval marks Zydus’s 424th FDA approval since 2003-04 and expands access to a treatment for this rare genetic disorder.